The isolation and characterisation of a bioactive polycyclic ether comprising a spiro-linked five-membered cyclic imine designated portimine (compound I) and the use of this compound and its congeners as synergists for antagonists of antiapoptotic proteins in the treatment of subjects with neoplasia.